Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Fineline Cube Sep 8, 2026
Company Medical Device

Lepu Medical Technology Receives NMPA Approval for MemoSorb Biodegradable PFO Occluder

Fineline Cube Sep 11, 2023

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Company Deals

EA Pharma and TransThera Sciences Collaborate on GI and Liver Disease Therapies

Fineline Cube Sep 11, 2023

Japan-based EA Pharma Co., Ltd and China-headquartered TransThera Sciences (Nanjing) Inc. have jointly announced the...

Company Deals

GRIT Biotechnology Secures RMB 400 Million in Series B Financing to Advance TIL Pipeline

Fineline Cube Sep 11, 2023

China-based GRIT Biotechnology has announced the completion of a Series B financing round, raising RMB...

Company Deals

Oriomics Secures Series B+ Funding to Advance Liver and Digestive Cancer Screening

Fineline Cube Sep 11, 2023

Hangzhou-based Oriomics, a specialist in cancer screening based on circulating tumor DNA (ctDNA) methylation detection,...

Company Drug

Sichuan Kelun Pharmaceutical Submits Biosimilar Cetuximab for NMPA Approval

Fineline Cube Sep 11, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech...

Company Deals

Biotyx Medical Secures Over RMB 200 Million in Series B Financing for Iron-Based Stents

Fineline Cube Sep 11, 2023

China-based Biotyx Medical (Shenzhen) Co.,Ltd, known as the world’s only developer of iron-based absorbable stents,...

Company Drug

United Laboratories’ UBT251 Receives Tacit Approval for NAFLD Clinical Study in China

Fineline Cube Sep 11, 2023

Hong Kong firm United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category...

Company Drug

Abbisko Therapeutics Receives EMA Approval for Phase III Study of Pimicotinib for TGCT

Fineline Cube Sep 11, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...

Company Drug

AriBio Files for Phase III Clinical Trial Approval in China for Alzheimer’s Drug AR1001

Fineline Cube Sep 11, 2023

South Korean clinical-stage biotech AriBio Co. has announced the filing for Phase III clinical trial...

Company Drug

Allist Pharmaceuticals and ArriVent Biopharma Release Promising Interim Data on Furmonertinib for NSCLC

Fineline Cube Sep 11, 2023

Shanghai-based biotech Allist Pharmaceuticals Co., Ltd and its US partner ArriVent Biopharma Inc. have jointly...

Company Deals

iotaSciences Partners with Quantum Design China for Single-Cell Handling Platform Distribution

Fineline Cube Sep 11, 2023

UK-based cell-line engineering firm iotaSciences has announced an exclusive partnership with Quantum Design China, a...

Company Drug

BMS Announces Positive Outcomes for BMS-986278 in Progressive Pulmonary Fibrosis Study

Fineline Cube Sep 11, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has released the final results from a Phase II trial...

Company Deals

Eurofarma Invests in Abcuro as Part of $100 Million Disruptive Startups and Biotech Initiative

Fineline Cube Sep 11, 2023

Brazil-based multinational company (MNC) Eurofarma has announced an investment in US immunotherapy developer Abcuro as...

Company Drug

EMA Reviews Janssen’s Balversa for Advanced Urothelial Carcinoma with FGFR3 Alterations

Fineline Cube Sep 11, 2023

The European Medicines Agency (EMA) has accepted for review a filing made by the Janssen...

Company Drug

United Laboratories Receives Tacit Approval for JAK1 Inhibitor TUL01101 Clinical Trial

Fineline Cube Sep 11, 2023

Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced tacit clinical trial approval...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Phase Ib/III Study of Dalpiciclib in mHSPC

Fineline Cube Sep 11, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval...

Company Deals

Otsuka and Shape Therapeutics Partner on Ophthalmology Gene Therapies Development

Fineline Cube Sep 11, 2023

Japan drug maker Otsuka (OTCMKTS: OTSKY) and US firm Shape Therapeutics have announced a strategic...

Company Drug

Roche and Alnylam’s Zilebesiran Achieves Primary Endpoint in Hypertension Phase II Trial

Fineline Cube Sep 8, 2023

Roche (SWX: ROG) and Alnylam (NASDAQ: ALNY) have announced that a Phase II trial for...

Policy / Regulatory

CDE Annual Report: Clinical Trials for Innovative Drugs in China Reach Record High

Fineline Cube Sep 8, 2023

The Center for Drug Evaluation (CDE) has released its annual report on clinical trials in...

Company Drug

Pfizer and Valneva’s Lyme Disease Vaccine VLA15 Shows Promise as Booster in Pediatric Trials

Fineline Cube Sep 8, 2023

Partners Pfizer (NYSE: PFE) and Valneva SE (NASDAQ: VALN) have revealed that their Lyme disease...

Posts pagination

1 … 527 528 529 … 718

Recent updates

  • Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections
  • China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback
  • Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation
  • CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally
  • Insilico Medicine Partners with Byterna Therapeutics to Build Next‑Generation mRNA AI‑Native R&D Engine – Targeting Circular mRNA Personalized Cancer Vaccines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Shionogi Wins TGA Marketing Authorization in Australia for Cefiderocol – Siderophore Cephalosporin Targeting Carbapenem‑Resistant Gram‑Negative Infections

Policy / Regulatory

China’s CDE Releases 110th Batch of Reference Preparations for Generic Quality and Consistency Evaluation – 27 New Drugs Added in Draft Open for Public Feedback

Company Deals

Shanghai Pharmaceuticals Signs Strategic Framework Pact with CAS Institute of Materia Medica to Bridge Drug Discovery and Industrial Translation

Company Deals

CanSino Biologics Signs Strategic Pact with DeepGeneAI to Co‑Develop mRNA Personalized Therapeutic Cancer Vaccines – Targeting GI and Rare Tumors Globally

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.